

2019

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature

Olga H. Orasan

George Ciulei

Sorina C. Coste

Bianca A. Cibu

Adela V. S Taut

See next page for additional authors

Follow this and additional works at: <https://scholar.valpo.edu/jmms>

 Part of the [Endocrinology, Diabetes, and Metabolism Commons](#), [Gastroenterology Commons](#), [Hepatology Commons](#), and the [Infectious Disease Commons](#)

Recommended Citation

Orasan, Olga H.; Ciulei, George; Coste, Sorina C.; Cibu, Bianca A.; Taut, Adela V. S; Tarmure, Simina F.; Pfingstgraf, Iulia O.; Alexescu, Teodora G.; Popovici, Ionela E.; Mureşan, Flaviu; Ovidiu, Fabian; Negrean, Vasile; and Cozma, Angela (2019) "The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature," *Journal of Mind and Medical Sciences*: Vol. 6 : Iss. 2 , Article 5.

DOI: 10.22543/7674.62.P210215

Available at: <https://scholar.valpo.edu/jmms/vol6/iss2/5>

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature

Authors

Olga H. Orasan, George Ciulei, Sorina C. Coste, Bianca A. Cibu, Adela V. S Taut, Simina F. Tarmure, Iulia O. Pfingstgraf, Teodora G. Alexescu, Ionela E. Popovici, Flaviu Mureşan, Fabian Ovidiu, Vasile Negrean, and Angela Cozma



Received for publication: February 24, 2019
Accepted: April 24, 2019

Review

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature

Olga H. Orasan¹, George Ciulei², Sorina C. Coste¹, Bianca A. Cibu³, Adela V. Sitar Taut¹, Simina F. Tarmure¹, Iulia O. Pfingstgraf⁴, Teodora G. Alexescu¹, Ionela E. Popovici¹, Flaviu Mureşan⁵, Fabian Ovidiu⁵, Vasile Negrean¹, Angela Cozma¹

¹Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, 4th Medical Department, Cluj-Napoca, Romania; ²Clinical Hospital C.F. Cluj, Republicii no. 18, zip code 400015, Cluj-Napoca, Romania; ³Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania; ⁴Iuliu Hațieganu University of Medicine and Pharmacy, Department of Physiopathology, Cluj-Napoca, Romania; ⁵Iuliu Hațieganu University of Medicine and Pharmacy, 4th Surgical Department, Cluj-Napoca, Romania

Abstract

The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but the invasiveness of this procedure is its major drawback. Different non-invasive tests have been used to study changes in the stage of liver fibrosis in patients with chronic viral hepatitis treated with the second-generation of direct-acting antiviral agents: liver stiffness measurements (with transient elastography or acoustic radiation force impulse elastography) or different scores that use serum markers to calculate a fibrosis score. We prepared a literature review of the available data regarding the long-term evolution of liver fibrosis after the treatment with direct-acting antiviral agents for chronic viral hepatitis C.

Keywords

: chronic viral hepatitis C, direct-acting antiviral agents, liver fibrosis

Highlights

- ✓ Transient elastography is the routine investigation for liver fibrosis monitoring in patients with chronic viral hepatitis C treated with direct acting antiviral agents.
- ✓ The APRI and FIB-4 scores registered the highest decrease between the baseline and the end of the treatment in patients with chronic viral hepatitis C treated with direct acting antiviral agents.

To cite this article: Orasan OH, Ciulei G, Coste SC, Cibu BA, Taut AVS, Tarmure SF, Pfingstgraf IO, Alexescu TG, Popovici IE, Mureşan F, Ovidiu F, Negrean V, Cozma A. The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature. *J Mind Med Sci.* 2019; 6(2): 210-215. DOI: 10.22543/7674.62.P210215

Introduction

The main objective in treating chronic viral hepatitis C (CHC) with the second-generation of direct-acting antiviral agents (DAAs) is to achieve a sustained virologic response (SVR). Reversing liver fibrosis in previously infected patients is a secondary goal, since achieving viral clearance does not reverse all the liver damage. DAAs do not have an anti-fibrotic effect (1). In patients who achieved SVR with interferon therapy (the previous standard of care in CHC), liver fibrosis regression was measured in 42% of the cases, while 53.1% of the patients did not have a significant change in the liver fibrosis stage, and fibrosis progression was reported in 4.6% of the patients (2).

In order to measure liver fibrosis, besides the gold standard of liver biopsy, various fibrosis scores calculated from routine laboratory tests have been developed and validated in recent years. These scores have numerous advantages, as they are neither invasive procedures nor expensive investigations. The aim of this article is to assess the changes that occur in liver fibrosis after SVR is achieved with DAAs, measured through liver biopsy and different non-invasive tests: transient elastography (TE), acoustic radiation force impulse elastography (ARFI), fibrosis-4 score (FIB-4), aspartate aminotransferase-platelet ratio index (APRI), and hyaluronic acid (HA).

Discussions

Transient Elastography (TE)

TE represents a non-invasive method of liver stiffness (LS) measurement which is used for fibrosis screening in various hepatic disorders as an alternative to liver biopsy (3). TE is routinely performed for liver fibrosis assessment prior to DAA therapy and also as a follow-up after achieving SVR (4-6).

A cohort study including adults with CHC who received DAA-based therapies reports a regression of >30% in LS measured by TE 12 months after the end of treatment (EOT) (7). Fibrosis regression was demonstrated in another study including patients with advanced fibrosis (F3-F4), who were monitored by TE at baseline, at EOT, and 12 weeks and 24 weeks after EOT (8). There were significant differences registered by TE between the baseline and EOT (8.3 kPa vs 7.4 kPa), EOT and 24-week SVR (7.4 kPa vs 5.3 kPa), and baseline and 48-week SVR (8.3 kPa vs 5.4 kPa) (9).

An improvement of LS was noticed in 82% of the patients with SVR at a 2-year follow-up. In 42% of the cases, liver fibrosis was decreased by at least 3 kPa (10).

Facciorusso et al. found an LS decrease from 12.3 kPa to 6.6 kPa at a 5-year follow-up after DAA therapy (11).

Another study with a long follow-up period (up to 72 weeks after EOT) indicated a significant and steady decline in LS values. The median LS values were 11.25 kPa before the initiation of treatment, 7.8 kPa at EOT, 6.45 kPa at 24 weeks of SVR, 6.25 kPa at 48 weeks of SVR, and 5.45 kPa at 72 weeks of SVR (12). In patients with liver cirrhosis, a large decrease in LS was observed, from a 32.5 kPa median at baseline to a 21.3 kPa median at EOT (13).

APRI

APRI is a simple-to-use liver fibrosis marker, calculated by applying the following formula: [Aspartate aminotransferase level (ULN)/platelet count (109/L)] *100 (14). The APRI test has a 65.1% sensitivity (Se) and 71.8% specificity (Sp) in detecting F2-F3, and 93.8% Se and 72.4% Sp in diagnosing liver cirrhosis. An APRI value of 0.77 differentiates F1 and F2, and a value of 0.84 is the cut-off between F3 and F4 (14, 15). APRI values decrease in CHC patients after treatment with DAAs, even in subjects who do not achieve SVR. In patients with SVR, the median APRI was lowered from 1.07 to 0.41. In non-SVR patients, the median value dropped from 2.05 to 1.13 (5). In another study, 48% of the patients had an APRI score higher than 1 at baseline, but after DAA treatment, only 7.7% had APRI values above 1 (16).

Median APRI values decrease significantly after 24 weeks of DAA therapy, from 1.4 to 0.5. After this period, the APRI stabilizes, and at 96 weeks after EOT no significant change is observed (17). Lledó et al. reported that the APRI index was decreased at EOT, but there was no significant variation in its values at 12-week SVR follow-up: 1.47 at baseline, 0.58 at EOT, and 0.54 at SVR (18). APRI regression is found in patients with liver transplant treated with DAAs (from 2.7±0.3 to 0.4±0.05 at 12-week SVR). Patients with severe inflammation or liver steatosis at baseline have greater improvements in the APRI index compared to those with lower inflammation and no steatosis (19). In the study conducted by Fabbri et al., APRI decreased in hepatitis C/HIV co-infected patients who underwent treatment with DAAs from a median of 0.94 to 0.37 (20).

Improvements in the APRI score after CHC treatment are explained by the normalization of liver enzymes and the increase in the number of platelets. Patients with F2-F3 have an improvement in APRI regardless of their treatment response. In patients with cirrhosis, fibrosis regression is significantly correlated with achieving SVR (21). In a study by Christian et al., the reduction in APRI was found

to be more pronounced in patients with F0-F2 compared to F3-F4 (22).

Tao et al. studied liver fibrosis regression in CHC patients infected with the genotype 3 variant of hepatitis C virus, treated with 3 different DAA regimens. This particular viral genotype has a faster progression of liver fibrosis to cirrhosis and shows more resistance to DAAs. A significant reduction in APRI was found after different DAA treatments, both in respondents (from 1.834 to 0.619, $p < 0.001$) and non-respondents (from 5.026 to 1.248, $p = 0.002$ for relapsed patients) (23).

Serum markers of liver fibrosis

Different serum biomarkers have been studied for the detection of liver fibrosis.

Hyaluronic acid (HA) was demonstrated to be useful for the detection of liver fibrosis in CHC patients, especially in cases where liver biopsy is restricted (such as end-stage renal disease) (24, 25). CHC patients who responded to treatment with daclatasvir and asunaprevir had a lower value of HA at SVR compared to the baseline values (123 ± 43 vs. 71 ± 14 ng/mL, $p < 0.01$), while non-respondents showed no significant difference before and after the treatment (145 ± 43 vs. 172 ± 46 ng/mL, $p = 0.465$) (26). The Enhanced Liver Fibrosis (ELF) score is an algorithm that uses age and serum levels of procollagen type III amino terminal propeptide, tissue inhibitor of metalloproteinases-1 and HA to give an estimate for liver fibrosis. In a sofosbuvir treatment study, the ELF score was decreased compared to the baseline (from 10.00 to 9.37, $p = 0.007$). Patients treated with sofosbuvir and pegylated interferon showed a temporary increase in HA measurements at 4 weeks during the treatment (from 59.5 to 177.9 mg/ml, $p = 0.002$), presumably because of the pro-inflammatory effect associated with the interferon therapy (6).

FIB-4

The FIB-4 score has been established alongside other non-invasive fibrosis scores in the international guidelines for the evaluation of liver fibrosis (15). The Apricot study developed a simple test using laboratory measurements to predict liver fibrosis in a large cohort of HIV/hepatitis C co-infected patients. The results of the study showed that age, serum aspartate aminotransferase, international normalized ratio, and platelet count were independent predictors of fibrosis. These variables were used to obtain the following formula: $\text{Age (years)} \times \text{aspartate aminotransferase [U/L]} / (\text{platelets [109/L]} \times (\text{alanine aminotransferase [U/L]})^{1/2})$, known today as the FIB-4 index (27). In a recent study on a multicenter real-world

cohort, significant liver fibrosis and cirrhosis were predicted with high accuracy by FIB-4 using TE as a reference (28).

FIB-4 has been validated for the evaluation of CHC and has acceptable Se and Sp, particularly in advanced fibrosis and cirrhosis. FIB-4 shows a significant decrease in all patients undergoing DAA treatment, especially in those achieving SVR ($p < 0.001$) (5). A significant decline in FIB-4 values is seen from baseline to 24 weeks after SVR ($p < 0.0001$) (11).

Another study proposed that a longer follow-up period could allow detection of LS changes unrelated to the decrease in the liver inflammatory activity, but rather associated with the improvement in liver architecture and function. Giannini et al. followed up 52 CHC patients for a median of 60 weeks after successful DAA treatment with SVR. FIB-4 values progressively decreased from baseline to the end of the follow-up period (16).

ARFI

ARFI is a novel procedure that enables the assessment of liver fibrosis during a conventional ultra-sonographic examination. This imaging technique quantifies the mechanical properties of tissues, without manual compression, by measuring the shear wave velocity induced by acoustic radiation and propagation in the liver tissue (29). Compared to TE, the elastography technique currently used in clinical practice, ARFI showed promising results in the assessment of liver fibrosis staging in CHC and HIV/hepatitis C co-infected patients (13, 30). Similar to other studies on patients with SVR after DAAs, the ARFI evaluation found that LS improves in patients with cirrhosis. Also, a decrease in LS was detected at 24 weeks after SVR by ARFI similar to TE (from 2.04 ± 0.62 m/s at baseline to 1.75 ± 0.57 m/s at 24 weeks after SVR) (31).

Liver biopsy

The degree of inflammation, the stage of fibrosis, and the histological improvement after achieving SVR are still best evaluated through liver biopsy (32). In addition to these findings, a recent short-term study evaluated 51 patients who underwent liver biopsies after SVR was achieved. Although liver enzymes normalized after achieving SVR, significant histological inflammation was still present in 16% of the patients (33).

Jason et al. tried to assess whether TE can be used in the management of patients with advanced fibrosis or cirrhosis, after achieving SVR, and compared the results to liver biopsy. In their study, there was discordance between post-SVR fibrosis stages predicted by TE vs. liver biopsy. Thus, it is unclear if TE following SVR can predict the fibrosis stage as reliably as liver biopsy (34).

Conclusions

TE has become a routine investigation for liver fibrosis monitoring in patients receiving treatment with DAAs, ARFI being another elastography method that can be used. The APRI and FIB-4 scores registered the greatest change when measured at EOT, since the platelet count and the liver aminotransferase values that make up their formulas showed the most significant improvement around that point. Serum markers such as HA, tissue inhibitor of metalloproteinases-1, and the combined ELF score also improve after the treatment with DAAs.

Acronyms and abbreviations

APRI – aspartate aminotransferase-platelet ratio index
 ARFI – acoustic radiation force impulse elastography
 CHC – chronic viral hepatitis C
 DAAs – direct-acting antiviral agents
 EOT – end of treatment
 FIB-4 – fibrosis-4 score
 HA – hyaluronic acid
 LS – liver stiffness
 Se – sensitivity
 Sp – specificity
 SVR – sustained virologic response
 TE – transient elastography.

Conflict of interest disclosure

There are no known conflicts of interest in the publication of this article. The manuscript was read and approved by all authors.

Compliance with ethical standards

Any aspect of the work covered in this manuscript has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

References

1. Lee YC, Hu TH, Hung CH, Lu SN, Chen CH, Wang JH. The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals. *PLoS One*. 2019; 14(4): e0214323.
2. Tachi Y, Hirai T, Ishizu Y, Honda T, Kuzuya T, Hayashi K. α -fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virologic response. *J Gastroenterol Hepatol*. 2016; 31(5): 1001-8.
3. Talwalkar J, Kurtz D, Schoenleber S, West C, Montori V. Ultrasound-Based Transient Elastography for the Detection of Hepatic Fibrosis: Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2007; 5(10): 1214-20.
4. Facciorusso A, Del Prete V, Turco A, Buccino RV, Nacchiero MC, Muscatiello N. Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: results from a 5-year cohort study. *J Gastroenterol Hepatol*. 2018; 33(4): 942-9.
5. Bachofner JA, Valli PV, Kroger A, Bergamin I, Künzler P, Baserga A, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. *Liver Int*. 2017; 37(3): 369-76.
6. Bernuth S, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A, et al. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. *Dig Liver Dis*. 2016; 48: 291-7.
7. Chan J, Gogela N, Zheng H, Lammert S, Ajayi T, Fricker Z et al. Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment. *Dig Dis Sci*. 2018; 63(2): 486-92.
8. Dolmazashvili E, Abutidze A, Chkhartishvili N, Karchava M, Sharvadze L, Tsertsvadze T. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. *Eur J Gastroenterol Hepatol*. 2017; 29(11): 1223-30.
9. Kobayashi N, Iijima H, Tada T, Kumada T, Yoshida M, Aoki T, et al. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. *Eur J Gastroenterol Hepatol*. 2018; 30(5): 546-51.
10. Flisiak R, Janczewska E, Łucejko M, Karpińska E, Zarębska-Michaluk D, Nazzal K, et al. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir \pm dasabuvir \pm ribavirin in the AMBER, real-world experience study. *J Viral Hepat*. 2018; 25(11): 1298-1305.

11. Pietsch V, Deterding K, Attia D, Ringe K, Heidrich B, Cornberg M et. al. Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. *United European Gastroenterol J.* 2018; 6(8): 1188-98.
12. Ogasawara N, Kobayashi M, Akuta N, Kominami Y, Fujiyama S, Kawamura Y, et al. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. *J Med Virol.* 2018; 90(2): 313-9.
13. Knop V, Hoppe D, Welzel T, et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. *J Viral Hepat.* 2016; 23(12): 994-1002.
14. El Serafy MA, Kassem AM, Omar H, Mahfouz MS, El Said, El Raziky M. APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis: Systematic review and meta-analysis. *Arab J Gastroenterol.* 2017; 18(2): 51-7.
15. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Hígado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol.* 2015; 63(1): 237-64.
16. Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, et al. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. *Eur J Clin Invest.* 2019; 49(3): e13056.
17. Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, et al. Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. *United European Gastroenterol J.* 2018; 6(8): 1188-119.
18. Lledó GM, Carrasco I, Benítez-Gutiérrez LM, Arias A, Royuela A, Requena S, et al. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. *AIDS.* 2018; 32(16): 2347-52.
19. Iacob S, Cerban R, Pietreanu C, Ester C, Iacob R, Gheorghe C, et al. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation. *J Gastrointestin Liver Dis.* 2018; 27(2): 139-44.
20. Fabbri G, Mastroianni I, Vergori A, Timelli L, Lorenzini P, Zaccarelli M, et al. Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus-coinfected patients treated with direct-acting antivirals. *HIV Med.* 2018; 19: 578-84.
21. El-Raziky M, Khairy M, Fouad A, Salama A, Elsharkawy A, Tantawy O. Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens. *J Interferon Cytokine Res.* 2018; 38(3): 129-36.
22. Mölleken C, Ahrens M, Schlosser A, Dietz J, Eisenacher M, Meyer HE, et al. Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. *Clin Mol Hepatol.* 2019; 25(1): 42-51.
23. Tao YC, Deng R, Wang ML, Lv DD, Yuan M, Wang YH, et al. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study. *Virol J.* 2018; 15(1): 150.
24. Orasan OH, Sava M, Iancu M, Cozma A, Saplonțai-Pop A, Sarlea Țărmure S, et al. Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients. *Int Urol Nephrol.* 2015; 47(7): 1209-17.
25. Orasan OH, Urian, L, Ciulei G, Breaban I, Stefan AM, Secara SC, et al. Thrombocytopenia in end-stage renal disease and chronic viral hepatitis B or C. *J Mind Med Sci.* 2018; 5(2): 236-243.
26. Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. *Hepatol Res.* 2016; 46(8): 758-64.
27. Holeab C, Paunica M, Curaj A. A complex method of semantic bibliometrics for revealing conceptual profiles and trends in scientific literature. The case of future-oriented technology analysis (FTA) science. *Economic computation and economic cybernetics studies and research.* 2017; 51(2): 23-37.
28. Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Günther R, et al. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. *J Viral Hepat.* 2019; 26(2): 224-30.

29. Friedrich-Rust M, Wunder K, Kriener S, Sotoudeh F, Richter S, Bojunga J, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. *Radiology*. 2009; 252: 595-604.
30. Chen SH, Lai HC, Chiang IP, Su WP, Lin CH, Kao JT, et al. Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients with Chronic Hepatitis C after Viral Eradication. *Clin Infect Dis*. 2019; ciz161.
31. Attia D, Deterding K, Cornberg J, Gebel MJ, Cornberg M, Manns MP, et al. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. *Eur J Gastroenterol Hepatol*. 2019; 31(1): 67-74.
32. Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and Kinetics of Decrease in Liver Stiffness after Antiviral Therapy in Patients with Chronic Hepatitis C: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2018; 16(1): 27-38.
33. Enomoto M, Ikura Y, Tamori A, Kozuka R, Motoyama H, Kawamura E, et al. Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. *United European Gastroenterol J*. 2018; 6(9): 1391-400.
34. Jason JP, Fei B, Emma D, Chase S, Catherine TF, Waalen J, et al. Morphometry Confirms Fibrosis Regression from Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C. *Hepatol Commun*. 2018; 2(11): 1320-30.